Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent

European Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2011, Pages 211-212

  Suarez Kurtz, Guilherme ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; CLOPIDOGREL; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; ESCITALOPRAM; PROTON PUMP INHIBITOR; TAXANE DERIVATIVE;

AFRICA; ALLELE; DRUG METABOLISM; ENZYME SUBSTRATE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LETTER; PHARMACOGENETICS; PRIORITY JOURNAL; PROGENY; RACE DIFFERENCE;

AFRICAN AMERICANS; ALLELES; ARYL HYDROCARBON HYDROXYLASES; HUMANS; LINKAGE DISEQUILIBRIUM;

EID: 79151474312     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0910-6     Document Type: Letter

References (16)

1. Pedersen RS, Brasch-Andersen C, Sim SC et al (2010) Linkage disequilibrium between the CYP2C19 17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations. Eur J Clin Pharmacol. doi: 10.1007/s00228-010-0864-8 2010
2. SC Sim C Risinger ML Dahl, et al. 2006 A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants Clin Pharmacol Ther 79 103 113 1:CAS:528:DC%2BD28XksVGltw%3D%3D 10.1016/j.clpt.2005.10.002 16413245
3. Suarez-Kurtz G, Genro JP, de Moraes MO et al (2010) Global pharmacogenomics: impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians Pharmacogenomics J (in press)
4. D Dai DC Zeldin JA Blaisdell, et al. 2001 Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid Pharmacogenetics 11 597 607 1:CAS:528:DC%2BD3MXotFWlt7c%3D 10.1097/00008571- 200110000-00006 11668219
5. I Cavaco R Piedade JP Gil V Ribeiro 2006 CYP2C8 polymorphism among the Portuguese Clin Chem Lab Med 44 168 170 1:CAS:528:DC%2BD28Xit1SisLs%3D 10.1515/CCLM.2006.030 16475901
6. S Parikh JB Ouedraogo JA Goldstein PJ Rosenthal DL Kroetz 2007 Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa Clin Pharmacol Ther 82 197 203 1:CAS:528:DC%2BD2sXptVyrsrw%3D 10.1038/sj.clpt.6100122 17361129
7. FC Parra RC Amado JR Lambertucci J Rocha CM Antunes SDJ Pena 2003 Color and genomic ancestry in Brazilians Proc Natl Acad Sci USA 100 177 182 1:CAS:528:DC%2BD3sXktlOgtg%3D%3D 10.1073/pnas.0126614100 12509516
8. G Suarez-Kurtz DD Vargens CJ Struchiner L Bastos-Rodrigues SDJ Pena 2007 Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms Pharmacogenet Genomics 17 765 771 1:CAS:528:DC%2BD2sXptVGlu7g%3D 10.1097/FPC.0b013e3281c10e52 17700365
9. W Kudzi AN Dodoo J Mills 2009 Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population BMC Med Genet 10 124 10.1186/1471-2350-10-124 19954515
10. BI Drögemöller GE Wright DJ Niehaus, et al. 2010 Characterization of the genetic profile of CYP2C19 in two South African populations Pharmacogenomics 11 1095 1103 10.2217/pgs.10.90 20712527
11. KR Ahmadi ME Weale ZY Xue, et al. 2005 A single-nucleotide polymorphism tagging set for human drug metabolism and transport Nat Genet 37 84 89 1:CAS:528:DC%2BD2cXhtFChsLzI 10.1038/ng0905-916 15608640
12. WC Speed SP Kang DP Tuck LN Harris KK Kidd 2009 Global variation in CYP2C8-CYP2C9 functional haplotypes Pharmacogenomics 9 283 290 1:CAS:528:DC%2BD1MXkslOgsL0%3D 10.1038/tpj.2009.10
13. RA Totah AE Rettie 2005 Cytochrome P450 C28: substrates, inhibitors, pharmacogentics and clinical relevance Clin Pharmacol Ther 77 341 352 1:CAS:528:DC%2BD2MXktFCrt70%3D 10.1016/j.clpt.2004.12.267 15900280
14. M Ingelman-Sundberg SC Sim A Gomez C Rodriguez-Antona 2007 Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects Pharmacol Ther 116 496 526 1:CAS:528:DC%2BD2sXhtlCrs7bE 10.1016/j.pharmthera.2007.09.004 18001838
15. A Li-Wan-Po T Girard P Farndon C Cooley J Lithgow 2010 Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C1917 Br J Clin Pharmacol 69 222 230 1:CAS:528:DC%2BC3cXktlSrsbw%3D 10.1111/j.1365-2125. 2009.03578.x 20233192
16. TR Gaun S Rodriguez INM Day 2007 Cubic exact solutions for the estimation of pairwise haplotype frequencies: implications for linkage disequilibrium analyses and a web tool 'CubeX' BMC Bioinform 8 428 10.1186/1471-2105-8-428